SS-31 (Elamipretide)
Cardiolipin-directed mitochondrial peptide
HUMAN AND PRECLINICAL EVIDENCE
10 mg · $65OPEN DOSSIER
OVERWATCH RESEARCH INTELLIGENCE // V7
RESEARCH
WITH CLARITY.
A tactical, evidence-aware platform for compound mechanisms, human data, preclinical findings, limitations, and research tools.
MISSION PROFILE // OW-V7
RESEARCH BEFORE ROUTINE
Mechanism is separated from outcome. Human evidence is separated from preclinical evidence.
23DOSSIERS
10RESEARCH AREAS
2CALCULATOR CENTERS
OVERWATCH STANDARDEvidence is labeled, not exaggerated.
HUMAN DATASeparated
PRECLINICALIdentified
LIMITATIONSVisible
01 // RESEARCH AREAS
Navigate by biological objective
Explore connected compounds through distinct scientific frames rather than duplicated product claims.
RESEARCH AREA
Weight Management
5 connected compound profiles with mechanism and evidence framing.
→RESEARCH AREA
Performance
3 connected compound profiles with mechanism and evidence framing.
→RESEARCH AREA
Recovery
4 connected compound profiles with mechanism and evidence framing.
→RESEARCH AREA
Cellular Health
4 connected compound profiles with mechanism and evidence framing.
→RESEARCH AREA
Longevity
4 connected compound profiles with mechanism and evidence framing.
→RESEARCH AREA
Hair & Skin
3 connected compound profiles with mechanism and evidence framing.
→RESEARCH AREA
Cognitive Research
3 connected compound profiles with mechanism and evidence framing.
→RESEARCH AREA
Hormonal Research
3 connected compound profiles with mechanism and evidence framing.
→RESEARCH AREA
Vitality Research
2 connected compound profiles with mechanism and evidence framing.
→RESEARCH AREA
Research Solutions
2 connected compound profiles with mechanism and evidence framing.
→02 // PRIORITY DOSSIERS
Featured research profiles
Retatrutide 10
Triple incretin receptor agonist research
HUMAN CLINICAL EVIDENCE
10 mg · $80OPEN DOSSIER
Wolverine
BPC-157 + TB-500 research blend
PRECLINICAL-LED EVIDENCE
10 mg · $80OPEN DOSSIER
Selank + Semax
Dual neuropeptide research blend
COMPONENT-DEPENDENT EVIDENCE
Research blend · ContactOPEN DOSSIER